S-1: Anteris Technologies Registers 9.1M Shares for Resale

Anteris Technologies Global Corp. filed an S-1 registration statement for the resale of up to 9.1 million common shares by selling stockholders, following a recent private placement and warrant issuance.

Summary

• Anteris Technologies Global Corp. has filed an S-1 registration statement to allow certain selling stockholders to resell up to 9,103,796 shares of common stock.
• The shares include 2,346,936 existing shares, 2,346,936 shares issuable upon exercise of Common Stock Warrants, 2,079,962 shares underlying CHESS Depositary Interests (CDIs), and 2,329,962 shares underlying CDIs issuable upon exercise of CDI Warrants.
• The company will not receive any proceeds from the resale of these shares by selling stockholders, but may receive up to approximately $40.4 million in aggregate gross proceeds if all warrants are exercised.
• Proceeds from warrant exercises are expected to fund the ongoing development of the DurAVR THV system, preparation and enrollment for the PARADIGM Trial, R&D for v2vmedtech, and general corporate purposes.
• Anteris is a structural heart company developing the DurAVR Transcatheter Heart Valve (THV) System for aortic stenosis, designed as a biomimetic valve with proprietary ADAPT tissue-enhancing technology.
• The PARADIGM Trial, a global pivotal study for the DurAVR THV System, formally initiated in October 2025 with the first European regulatory clearance in Denmark and subsequent patient enrollment.
• The U.S. FDA granted Investigational Device Exemption (IDE) approval for the PARADIGM Trial in the fourth quarter of 2025.
• The company is a development-stage entity that has incurred net losses each year since its inception and currently generates small amounts of revenue.
• The global market opportunity for TAVR in severe aortic stenosis and valve-in-valve (ViV) procedures is projected to reach $9.9 billion and $2.5 billion, respectively, by 2028, according to Future Market Insights (FMI).

Sentiment

Score: 6

Explanation: The filing presents a mixed outlook. Positives include significant progress in clinical trials (PARADIGM Trial initiation, FDA IDE approval), a large and growing target market, and a potentially disruptive product. However, the company is in a development stage with recurring net losses, and its auditor has raised 'substantial doubt about its ability to continue as a going concern,' indicating significant financial challenges and risks. The capital raise through warrants is positive, but the proceeds are contingent on exercise.

Positives

• The DurAVR THV System is a first-in-class biomimetic valve designed to replicate normal aortic blood flow and potentially offer increased durability, addressing unmet needs in the TAVR market.
• The PARADIGM Trial, a randomized global pivotal study, has formally initiated with European regulatory clearance in Denmark and FDA IDE approval in Q4 2025, marking significant clinical progress.
• The company's proprietary ADAPT tissue technology has been clinically demonstrated to be calcium-free for up to 10 years post-procedure and has been used in over 55,000 patients globally in other indications.
• The TAVR market is large, underpenetrated, and growing, with the global opportunity for severe aortic stenosis and ViV procedures expected to reach $9.9 billion and $2.5 billion, respectively, by 2028.
• The recent private placement and potential warrant exercises could provide up to $40.4 million in capital for ongoing development and clinical trials.

Negatives

• Anteris Technologies Global Corp. is a development-stage company that has incurred recurring net losses each year since its operation.
• The company generates small amounts of revenue and income, which are insufficient to cover its investment in research, development, and operational activities.
• The audit report for the year ended December 31, 2024, contains an explanatory paragraph indicating substantial doubt about the company's ability to continue as a going concern.
• The medical device development and commercialization industry is highly competitive, with established competitors possessing greater capital resources and market share.
• There is no assurance that holders of the warrants will elect to exercise any or all of them, meaning the potential $40.4 million in proceeds is not guaranteed.

Risks

• Sufficiency of capital resources and the ability to raise additional funding when needed.
• Risks associated with current and future research and development activities, including clinical testing, manufacturing, and related costs and timing.
• Uncertainties regarding product development and business strategy, including the potential size of markets for products and future development/expansion.
• Challenges in commercializing products and generating product revenues.
• Risks concerning anticipated regulatory activities, including the ability to obtain regulatory clearances.
• Operational risks and risks related to intellectual property.
• The global, North American, and European TAVR markets may not grow at the rate projected by market data or at all, which could materially and adversely affect the business and stock price.
• The company's status as a development-stage entity with limited resources and a smaller capital base poses challenges to implementing its business strategy.

Future Outlook

The company anticipates that data from the PARADIGM Trial will provide the primary clinical evidence required for regulators to approve commercialization, including Premarket Approval (PMA) in the United States and CE Mark approval. Management expects to use proceeds from warrant exercises for ongoing development of the DurAVR THV system, PARADIGM Trial activities, R&D for v2vmedtech, and general corporate purposes. The global TAVR market for severe aortic stenosis and valve-in-valve procedures is projected to grow significantly, reaching $9.9 billion and $2.5 billion respectively by 2028.

Management Comments

• We believe that we have significant growth potential in a large, underpenetrated and growing market.
• Our first in class DurAVR THV System is a single-piece valve with a novel, biomimetic design that aims to replicate the normal blood flow of a healthy human aortic valve.
• We believe our ADAPT anti-calcification tissue can result in improved hemodynamics as compared to traditional three-piece designs, aiming to increase durability and last longer.
• We intend to test these features in the DurAVR THV System randomized, global pivotal study (the PARADIGM Trial) against commercially approved TAVR devices.
• Our management will have broad discretion over the use of proceeds from the exercise of the Warrants.

Industry Context

Anteris operates in the highly competitive and rapidly advancing structural heart medical device industry, specifically targeting aortic stenosis with its Transcatheter Aortic Valve Replacement (TAVR) system. The TAVR market has seen significant growth since FDA approval for high-risk patients in 2011 and low-risk patients in 2019, with a substantial underpenetrated patient population. Anteris's biomimetic design and ADAPT tissue technology aim to differentiate it from traditional three-piece TAVR devices, positioning it for younger, more active patients who require longer durability and pre-disease hemodynamics, aligning with the trend of earlier diagnosis and treatment of aortic stenosis.

Comparison to Industry Standards

• The DurAVR THV System is described as a 'first in class' biomimetic valve, aiming to replicate normal aortic blood flow, which differentiates it from 'traditional three-piece aortic valves' and 'previous generations of TAVRs' designed for older, high-risk patients.
• The company's ADAPT tissue technology has been clinically demonstrated to be calcium-free for up to 10 years post-procedure, a key durability claim compared to other TAVR devices.
• The PARADIGM Trial is designed as a randomized, controlled multicenter, international study, comparing the DurAVR THV against 'commercially available and approved THV devices,' indicating a direct comparison to industry standards.
• The global TAVR market opportunity for severe aortic stenosis is projected to reach $9.9 billion by 2028, and for valve-in-valve (ViV) procedures, $2.5 billion by 2028, according to FMI, providing a benchmark for market potential.

Corporate Governance

Related Party Transactions

• L1 Capital Pty Ltd, a beneficial owner of greater than 10% of outstanding Common Stock prior to the Private Placement, agreed not to exercise its CDI Warrants to the extent such exercise would result in its beneficial ownership exceeding 19.99%.
• Sio Capital Management, LLC, an affiliate of Sio Partners and Sio Partners Offshore, was a beneficial owner of greater than 5% of outstanding Common Stock prior to the Private Placement.

Stakeholder Impact

• **Shareholders:** Potential dilution from the exercise of warrants, but also potential for capital infusion to fund product development and clinical trials. The resale registration allows existing investors liquidity. Anti-takeover provisions may limit shareholder influence on corporate control.
• **Employees:** Continued investment in R&D and operational scale-up suggests job stability and potential growth opportunities.
• **Customers (future patients):** Continued development and clinical trials of the DurAVR THV System aim to provide an innovative treatment option for aortic stenosis, potentially improving quality of life.
• **Creditors:** The 'going concern' explanatory paragraph in the audit report may raise concerns, but potential warrant exercise proceeds could improve financial stability.
• **Suppliers:** Ongoing R&D and manufacturing scale-up activities indicate continued demand for supplies and services.

Next Steps

• Continue ongoing development of the DurAVR THV system.
• Prepare for and enroll patients in the PARADIGM Trial for DurAVR THV system.
• Continue ongoing research and development for v2vmedtech.
• Strengthen operational infrastructure, including quality management system buildout and manufacturing scale-up.
• Seek ISO 13485 certification.
• Obtain Premarket Approval (PMA) for DurAVR THV System in the United States.
• Obtain CE Mark approval for DurAVR THV System in Europe.
• Selling stockholders may offer, sell or distribute registered shares publicly or privately.

Key Dates

Keywords

Anteris Technologies, DurAVR THV System, Transcatheter Heart Valve, Aortic Stenosis, TAVR, ADAPT tissue technology, PARADIGM Trial, SEC S-1 filing, Resale Registration, Private Placement, Warrants, Medical Device, Cardiology, Biomimetic Valve